Vendor Intelligence Report: Qing Li Peptide

Executive summary

Across 323 Finnrick lab tests, Qing Li Peptide posts 208 pass / 114 fail results, for a 64% overall pass rate. The signal is dispersion: GHK-Cu is strongest, tirzepatide and retatrutide are more defensible GLP-1 choices, and TB-500 is the clearest warning flag. Ratings contract under stricter grading, so the public score should not be used alone.

The non-lab record is more severe. Domain and archive evidence begins in late 2024 while Qing Li presents a longer history, and an early Wayback capture of the same domain shows a steroid-selling storefront before the current Western-facing peptide brand. The clearest supplier trail points to a small Yiwu trading firm, not a disclosed Hong Kong manufacturer; the privacy policy names no contracting entity.

The report maps a multi-brand apparatus. Qing Li’s employee-verification portal exposed staff records during the field run, while sister sites reuse the same faces under different Western names beside a shared “Joe” contact and Hong Kong footer entities. Buyer reports add a separate risk: crypto-paid orders, customs-delay explanations, dark staff numbers, and Pioneer Peptide appearing as a secondary fee-demand channel.

The practical read is narrow: Qing Li may be a relatively better choice for products that test well, but it is a poor place to use irreversible payment rails or experiment with fail-heavy peptides. Batch-specific lab verification and channel verification matter here, and neither solves the separate refund and delivery-risk pattern.

Inside the full report:

• Appendix A with per-product pass/fail rates and methodology-divergence charts for all 13 tested products
• RDAP, Wayback and Global Sources chronology behind the history-claim mismatch
• Corporate-identity map covering the Yiwu supplier record, Hong Kong footer entities and unresolved registry checks
• Employee-verification API findings and staff-photo reuse across Qing Li, Weitai Global and Peptides Factory
• Pioneer Peptide buyer-report pattern with captured Reddit threads and payment-rail evidence
• Identifier ledger for domains, staff email infrastructure, contacts, addresses and open re-check leads

Risk assessment

• Product-specific quality failure risk — high: TB-500 (22%), Tesamorelin (34.09%), BPC-157 (36.75%) and CJC-1295 (37.68%) are fail-heavy; GHK-Cu, tirzepatide and retatrutide are stronger relative choices but not a blanket pass.
• Non-delivery and advance-fee fraud risk — high: Public buyer reports describe crypto-paid Qing Li orders delayed, shorted or blocked, followed by Pioneer Peptide demands for extra refundable customs or shipping fees.
• Corporate identity and history-claim risk — high: The 7+ years and © 2012 history are unsupported by RDAP, Wayback and Global Sources records; the clearest entity record is a 2024 Yiwu trading firm, not a disclosed Hong Kong manufacturer.
• Brand-confusion and verification-control risk — high: Weitai Global and Peptides Factory reuse Qing Li staff photos, copy and contacts, Pioneer Peptide appears in complaints, and no authorized-channel or signed batch-COA system was found.
• Payment recourse risk — high: Crypto, stablecoins and bank-transfer rails are accepted while the captured refund language centers PayPal; reported losses occurred on irreversible rails.
• Unverified GMP and prior steroid-footprint risk — medium: A January 2025 same-domain archive sold steroids and claimed 20+ years; current co-handling is not proven, but Qing Li’s GMP claim was not verified.